MMIT Reality Check on Low Testosterone (May 2020)

According to our recent payer coverage analysis for low testosterone treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for low testosterone treatments shows that under the pharmacy benefit, about 58% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In February 2020, Clarus Therapeutics, Inc. said that its Jatenzo (testosterone undecanoate) is available by prescription in the U.S. In March 2019, the FDA approved the medication for the treatment of males with low testosterone levels because of specific genetic disorders or pituitary glanddamaging tumors.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_Diabetes.jpg
November 24

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/wordpress-featured-image-reality-check-colorectal-cancer.jpg
November 19

MMIT Reality Check on Colorectal Cancer

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/wordpress-featured-image-reality-check-cystic-fibrosis.jpg
November 12

MMIT Reality Check on Cystic Fibrosis

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today